Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival

0552664 - ÚEM 2022 RIV GB eng J - Článek v odborném periodiku
Gentiluomo, M. - Corradi, Ch. - Vanella, G. - Johansen, A. - Strobel, C. - Szentesi, A. - Milanetto, A.C. - Hegyi, P. - Kupcinskas, J. - Tavano, F. - Neoptolemos, J.P. - Bozzato, D. - Hackert, T. - Pezzilli, R. - Johansen, J.S. - Costello, E. - Mohelníková-Duchoňová, B. - Eijck, C.H.J. - Talar-Wojnarowska, R. - Hansen, C.P. - Darvasi, E. - Chen, I.M. - Cavestro, G.M. - Souček, P. - Piredda, L. - Vodička, Pavel - Gazouli, M. - Arcidiacono, P.G. - Canzian, F. - Campa, D. - Capurso, G.
Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival.
Scientific Reports. Roč. 11, č. 1 (2021), č. článku 7570. ISSN 2045-2322. E-ISSN 2045-2322
Institucionální podpora: RVO:68378041
Klíčová slova: genome-wide association * susceptibility loci * identifies variants * cancer risk * polymorphisms
Obor OECD: Genetics and heredity (medical genetics to be 3)
Impakt faktor: 4.997, rok: 2021
Způsob publikování: Open access
https://www.nature.com/articles/s41598-021-87130-0

Although pancreatic ductal adenocarcinoma (PDAC) survival is poor, there are differences in patients' response to the treatments. Detection of predictive biomarkers explaining these differences is of the utmost importance. In a recent study two genetic markers (CD44-rs353630 and CHI3L2-rs684559) were reported to be associated with survival after PDAC resection. We attempted to replicate the associations in 1856 PDAC patients (685 resected with stage I/II) from the PANcreatic Disease ReseArch (PANDoRA) consortium. We also analysed the combined effect of the two genotypes in order to compare our results with what was previously reported. Additional stratified analyses considering TNM stage of the disease and whether the patients received surgery were also performed. We observed no statistically significant associations, except for the heterozygous carriers of CD44-rs353630, who were associated with worse OS (HR=5.01, 95% CI 1.58-15.88, p=0.006) among patients with stage I disease. This association is in the opposite direction of those reported previously, suggesting that data obtained in such small subgroups are hardly replicable and should be considered cautiously. The two polymorphisms combined did not show any statistically significant association. Our results suggest that the effect of CD44-rs353630 and CHI3L2-rs684559 cannot be generalized to all PDAC patients.
Trvalý link: http://hdl.handle.net/11104/0327783